SCHEMBL15469445

SCHEMBL15469445

Cc1ccc([C@@]2(NC(=O)Nc3ccc(F)cc3)CCOc3cccnc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.44
▸ NPC1 O15118 6/20 0.44
▸ TRPM8 Q7Z2W7 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ TP53 P04637 3/20 0.39
▸ GBA1 P04062 1/20 0.38
▸ GRIN2B Q13224 1/20 0.37
▸ FPR2 P25090 1/20 0.36
▸ P2RY1 P47900 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MGAT2 Q10469 1/20 0.36
▸ MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15469442 0.90 NPC1 (0.47) RAB9ANPC1TRPM8SMN1; SMN2L3MBTL1
SCHEMBL15467435 0.90 TRPM8 (0.46) RAB9ANPC1TRPM8P2RY1
SCHEMBL15467437 0.90 TRPM8 (0.46) RAB9ANPC1TRPM8P2RY1
SCHEMBL15469443 0.86 NPC1 (0.50) RAB9ANPC1TRPM8SMN1; SMN2CYP1A2
SCHEMBL15469370 0.86 TRPM8 (0.55) RAB9ANPC1TRPM8L3MBTL1KDM4E
SCHEMBL16413921 0.82 TRPM8 (0.49) RAB9ANPC1TRPM8CYP2C9CYP2C19
SCHEMBL16413920 0.82 TRPM8 (0.49) RAB9ANPC1TRPM8CYP2C9CYP2C19
SCHEMBL15567708 0.82 TRPM8 (0.49) RAB9ANPC1TRPM8CYP2C9CYP2C19
SCHEMBL16418668 0.81 TRPM8 (0.42) RAB9ANPC1TRPM8SMN1; SMN2KDM4E
SCHEMBL15469434 0.81 TRPM8 (0.40) RAB9ANPC1TRPM8KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 — — US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 — — US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 RAB9A 1056/4885NPC1 702/4885TRPM8 1/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 RAB9A 1056/4885NPC1 702/4885TRPM8 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback